CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities:
Net loss	$ (5,851,067)	$ (5,838,654)
Adjustments to reconcile net loss to net cash flows from operating activities, net of effects of acquisition:
Depreciation	231,862	223,264
Amortization of intangible assets	667,954	333,966
Amortization of debt discount and deferred financing costs	133,517	499,610
Employee share-based compensation expense	809,469	460,756
Other share-based compensation expense	222,208	42,554
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(559,044)	(380,565)
Inventory	(103,257)	(64,408)
Prepaid expenses and other current assets	(140,508)	(704)
Other assets	0	96,702
Accounts payable and accrued expenses	574,521	726,919
Accrued interest	37,698	0
Other liabilities	57,127	0
Net cash flows from operating activities	(3,919,520)	(3,900,560)
Cash flows from investing activities:
Purchase of equipment	(143,427)	(120,367)
Cash paid in conjunction with acquisition	(466,417)	0
Net cash flows from investing activities	(609,844)	(120,367)
Cash flows from financing activities:
Proceeds from Line of Credit with Related Party	1,300,000	0
Repayment of Line of Credit	(99,000)	0
Repayment of Notes Payable	(30,932)	0
Proceeds from sale of common stock and warrants and common stock with registration rights, net	3,632,721	785,000
Proceeds from exercise of stock options	3	102,626
Proceeds from exercise of warrants	0	3,207,969
Net cash flows from financing activities	4,802,792	4,095,595
Net change in cash	273,428	74,668
Cash, beginning of period	1,340,922	2,653,537
Cash, end of period	1,614,350	2,728,205
Supplemental disclosure of cash flow information:
Cash paid for interest	2,833	0
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activity:
Outstanding convertible debt and accrued interest
Stock valued in conjunction with its acquisition of Surgical Biologics, LLC	7,087,500
Beneficial conversion feature value related to the convertible debt issued with regard to its acquisition of Surgical Biologics, LLC	437,500
Beneficial conversion feature related to convertible line of credit	$ 80,000